Molecular Templates (MTEMQ) AI Stock Analysis

• Market Cap: $658.00
• Dividend Yield: N/A
• Average Volume (3M): 9.78M
• Price to Earnings (P/E): ―
• Beta (1Y): -168.33
• Revenue Growth: -49.41%
• EPS Growth: 78.46%
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -2.70
• Shares Outstanding: 6,583,880
• 10 Day Avg. Volume: 221,309
• 30 Day Avg. Volume: 9,778,840
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 36 Underperform
• Price Target: ―

Molecular Templates is facing a challenging financial and operational environment. The company's high leverage, negative cash flow, and recent strategic decision to wind down operations heavily impact the overall score. While there are minor positive signs in revenue growth, the technical analysis, valuation concerns, and adverse corporate events contribute significantly to the low score.

Molecular Templates Business Overview & Revenue Model

Company Description

Molecular Templates, Inc. (MTEM) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The company operates primarily in the biotechnology sector, utilizing its proprietary engineered toxin body platform technology to create novel therapies aimed at treating cancer and other serious diseases. Molecular Templates strives to enhance the potency and specificity of its therapeutics to improve patient outcomes.

How the Company Makes Money

Molecular Templates generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments, and potential royalties on sales of successfully developed therapies. The company's proprietary platform technology is a key asset in forming these partnerships, offering unique treatment mechanisms that attract interest from industry leaders. Additionally, MTEM may receive funding from grants and government contracts to support its research and development activities, although these are not the primary sources of income.

Molecular Templates Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Molecular Templates Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
FATE	46 Neutral	$132.97M	―	-49.23%	―	105.85%	22.13%
ADAP	41 Neutral	$65.24M	―	-273.36%	―	883.05%	62.93%
KPTI	38 Underperform	$38.79M	―	41.08%	―	1.19%	61.65%
MTEMQ	36 Underperform	$658.00	―		―	-49.41%	78.46%

Molecular Templates Corporate Events

Molecular Templates Announces Leadership Changes and Operational Wind Down

Molecular Templates announced significant changes in its leadership, with multiple resignations from its Board of Directors and the resignation of Dr. Eric E. Poma from several executive roles. These changes are part of a strategic decision to wind down the company’s operations, with Craig Jalbert appointed as the sole director to oversee this process. The company has cautioned stakeholders about the speculative nature of trading its securities, indicating that current trading prices may not reflect actual value and that investors are unlikely to realize returns on their investments.

Molecular Templates Announces Key Leadership Transition

Jason Kim has resigned as the Company’s President, CFO, and Treasurer, effective December 8, 2024, with no disagreements or severance involved. Kim will continue to consult until year-end while his stock options vest. Eric Poma, the CEO and Chief Scientific Officer, steps in as Interim CFO, leveraging his extensive experience in biotechnology and company leadership to guide the financial helm during this transitional period.